Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001

BACKGROUND: Pembrolizumab plus lenvatinib is a novel combination with promising efficacy in patients with advanced and recurrent endometrial cancer. This combination demonstrated high objective response rates in a single-arm phase 1b/2 trial of lenvatinib plus pembrolizumab in patients with advanced...

Descripción completa

Detalles Bibliográficos
Autores principales: Marth, Christian, Tarnawski, Rafal, Tyulyandina, Alexandra, Pignata, Sandro, Gilbert, Lucy, Kaen, Diego, Rubio, M Jesús, Frentzas, Sophia, Beiner, Mario, Magallanes-Maciel, Manuel, Farrelly, Laura, Choi, Chel Hun, Berger, Regina, Lee, Christine, Vulsteke, Christof, Hasegawa, Kosei, Braicu, Elena Ioanna, Wu, Xiaohua, McKenzie, Jodi, Lee, John J, Makker, Vicky
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8762038/
https://www.ncbi.nlm.nih.gov/pubmed/34799418
http://dx.doi.org/10.1136/ijgc-2021-003017

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8762038/
https://www.ncbi.nlm.nih.gov/pubmed/34799418
http://dx.doi.org/10.1136/ijgc-2021-003017

Ejemplares similares